Survival [acty]
Myocardial Infarction [dsyn]
Relationship [qlco]
Thrombolysis [clna]
Discharge [bdsu]
Medication [phsu]
Myocardial Infarction [dsyn]
Follow-up Study [resa]
Large [qnco]
randomized [resa]
TRAIL [gngm]
Thrombolysis [clna]
long-term treatment [hlca]
Beta-Blockers [phsu]
Antiplatelet Drugs [phsu]
Angiotensin-Converting Enzyme Inhibitors [phsu]
Survival [acty]
Acute myocardial infarction [dsyn]
Calcium Channel Blockers [phsu]
Nifedipine [orch, phsu]
Diltiazem [orch, phsu]
Verapamil [orch, phsu]
Benefit [qnco]
effects [qlco]
Reported [inpr]
subgroups [virs]
Raised [qnco]
Concern [idcn]
Safety [hcpp]
Drug [phsu]
Class [inpr]
Patients [podg]
coronary heart disease [dsyn]
Study [mnob]
Survival [acty]
{Non-patient} [clna]
diabetic [fndg]
Population-Based Registry [inpr]
Acute myocardial infarction [dsyn]
Germany [geoa]
Aged [orga]
SURVIVE [phsu]
First myocardial infarction [dsyn]
q wave [diap]
acute [tmco]
days [tmco]
IMPACT [gngm]
Thrombolysis [clna]
prescribed [hlca]
Medication [phsu]
Discharge [bdsu]
Antiplatelet Drugs [phsu]
Calcium Channel Blockers [phsu]
Survival [acty]
Proportional Hazard Model [inpr, qnco]
controlling [ftcn]
Age [orga]
Sex [orgf]
Concomitant [tmco]
Cardiac drug [phsu]
Thrombolysis [clna]
Risk Ratio [qnco]
Beta [plnt]
Blockade [ftcn]
drug use [mobd]
reductions [npop]
Mortality [qnco]
Calcium Channel Blockers [phsu]
reduction [npop]
Mortality [qnco]
Separate [spco]
Nifedipine [orch, phsu]
Diltiazem [orch, phsu]
CI-2 [aapp, phsu]
Increased [qnco]
Patients [podg]
Beta-Blockers [phsu]
Reference [idcn]
Prescription [hlca]
Calcium Channel Blockers [phsu]
Increased [qnco]
Mortality [qnco]
Nifedipine [orch, phsu]
Beta-Blockers [phsu]
Diltiazem [orch, phsu]
Beta-Blockers [phsu]
CI 4 [aapp, phsu]
Observational Study [resa]
Benefit [qnco]
Thrombolysis [clna]
Beta [plnt]
adrenergic [ftcn]
Blockade [ftcn]
drug use [mobd]
Survival [acty]
Acute myocardial infarction [dsyn]
Patients [podg]
Calcium channel blocker [phsu]
APPEAR [qlco]
Increased [qnco]
Support [medd]
Need [qlco]
Controlled [ftcn]
Trial [resa]
Address [inpr]
Issue [fndg]
